- Home
- ATCH vs PCSA Comparison
ATCH vs PCSA Comparison
Compare ATCH & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATCH
- PCSA
- Stock Information
- Founded
- ATCH 2022
- PCSA 2011
- Country
- ATCH United States
- PCSA United States
- Employees
- ATCH N/A
- PCSA 13
- Industry
- ATCH
- PCSA Biotechnology: Pharmaceutical Preparations
- Sector
- ATCH
- PCSA Health Care
- Exchange
- ATCH Nasdaq
- PCSA Nasdaq
- Market Cap
- ATCH 3.4M
- PCSA 1.2M
- IPO Year
- ATCH N/A
- PCSA N/A
- Fundamental
- Price
- ATCH $0.42
- PCSA $0.24
- Analyst Decision
- ATCH
- PCSA Strong Buy
- Analyst Count
- ATCH 0
- PCSA 1
- Target Price
- ATCH N/A
- PCSA $6.00
- AVG Volume (30 Days)
- ATCH 653.2K
- PCSA 6.0M
- Earning Date
- ATCH 05-27-2025
- PCSA 05-09-2025
- Dividend Yield
- ATCH N/A
- PCSA N/A
- EPS Growth
- ATCH N/A
- PCSA N/A
- EPS
- ATCH 2.67
- PCSA N/A
- Revenue
- ATCH N/A
- PCSA N/A
- Revenue This Year
- ATCH N/A
- PCSA N/A
- Revenue Next Year
- ATCH N/A
- PCSA N/A
- P/E Ratio
- ATCH $0.16
- PCSA N/A
- Revenue Growth
- ATCH N/A
- PCSA N/A
- 52 Week Low
- ATCH $0.42
- PCSA $0.22
- 52 Week High
- ATCH $84.00
- PCSA $3.10
- Technical
- Relative Strength Index (RSI)
- ATCH 29.02
- PCSA 32.49
- Support Level
- ATCH $0.48
- PCSA $0.20
- Resistance Level
- ATCH $0.60
- PCSA $0.25
- Average True Range (ATR)
- ATCH 0.07
- PCSA 0.06
- MACD
- ATCH 0.07
- PCSA 0.01
- Stochastic Oscillator
- ATCH 5.45
- PCSA 32.69
About ATCH AtlasClear Holdings Inc. Common Stock
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and innovative financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).